GIỚI THIỆU VỀ TẬP NÀY
Pancreatic cancer remains one of the most difficult cancers to treat, in part because mutations in the KRAS gene are extraordinarily common in pancreatic ductal adenocarcinoma (PDAC). These mutations keep growth-promoting signals switched on, allowing cancer cells to proliferate and survive. Although drugs targeting certain KRAS mutations have emerged in recent years, they work against only a subset of mutant forms, leaving a need for strategies capable of targeting a broader range of KRAS-driven cancers.
A research paper published in Volume 17 of Oncotarget, titled “The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation,” investigated a class of experimental compounds known as polyisoprenylated cysteinyl amide inhibitors, or PCAIs. Rather than simply shutting down signaling pathways normally associated with cancer growth, the researchers uncovered a more unexpected effect: PCAIs pushed some of these pathways into unusually high activity while simultaneously promoting oxidative stress, disrupting cell structure, and triggering cancer cell death.
Full blog post - https://www.oncotarget.org/2026/08/24/experimental-compounds-push-cancer-promoting-pathways-into-overdrive-in-pancreatic-cancer-cells/
DOI - https://doi.org/10.18632/oncotarget.28879
Correspondence to - Nazarius S. Lamango - nazarius.lamango@famu.edu
Abstract video - https://www.youtube.com/watch?v=asbhjME7rFQ
Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28879
Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/
Keywords - cancer, PCAIs, PDAC, MAPK, PI3K/AKT, KRAS
To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media:
Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh
MEDIA@IMPACTJOURNALS.COM
A research paper published in Volume 17 of Oncotarget, titled “The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation,” investigated a class of experimental compounds known as polyisoprenylated cysteinyl amide inhibitors, or PCAIs. Rather than simply shutting down signaling pathways normally associated with cancer growth, the researchers uncovered a more unexpected effect: PCAIs pushed some of these pathways into unusually high activity while simultaneously promoting oxidative stress, disrupting cell structure, and triggering cancer cell death.
Full blog post - https://www.oncotarget.org/2026/08/24/experimental-compounds-push-cancer-promoting-pathways-into-overdrive-in-pancreatic-cancer-cells/
DOI - https://doi.org/10.18632/oncotarget.28879
Correspondence to - Nazarius S. Lamango - nazarius.lamango@famu.edu
Abstract video - https://www.youtube.com/watch?v=asbhjME7rFQ
Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28879
Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/
Keywords - cancer, PCAIs, PDAC, MAPK, PI3K/AKT, KRAS
To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media:
Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh
MEDIA@IMPACTJOURNALS.COM
Tiếng Anh
Hoa Kỳ
BẢN CHÉP ÂM THANH 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
TÌM KIẾM CÁC TẬP TRƯỚC
Tìm kiếm các tập trước của Oncotarget.
CÁC TẬP KHÁC TRONG PODCAST NÀY
BUFFALO, NY – August 10, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on August 7, 2026, titled “Delayed growth of SK-ES-1 Ewing sarcoma tumor xenografts is associated with reduced Trk and IGF1R pathway markers.”
The study was led by first author Bruna Almeida dos Santos …
BUFFALO, NY – August 25, 2026 – A new precision oncology paper was #published in Volume 17 of Oncotarget on August 14, 2026, titled “Systematic methodological flaws in DNA contamination assessment of mRNA vaccines: A critical analysis of Achs et al. (2025).”
The article was led by first and corres…
BUFFALO, NY – August 31, 2026 – A new #editorial was published in Volume 17 of Oncotarget on June 8, 2026, titled “Tumor infiltrating lymphocyte (TIL) therapy for treating the solid tumors: Challenges and future perspectives.”
The editorial was led by first and corresponding author Bhartendra Shar…
BUFFALO, NY – August 28, 2026 – A new #research paper was published in Volume 17 of Oncotarget on August 19, 2026, titled “Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine.”
The study was led by first author Kelly Crane from the Department of Ur…
Tuyên bố miễn trừ trách nhiệm: Podcast và tác phẩm nghệ thuật được nhúng trên trang này là của Oncotarget Podcast, là tài sản của chủ sở hữu và không được liên kết hoặc xác nhận bởi Listen Notes, Inc.
CHỈNH SỬA
Cảm ơn bạn đã giúp cơ sở dữ liệu podcast luôn cập nhật.